Protalix BioTherapeutics lifts revenue on strong Elfabrio demand

Protalix BioTherapeutics reported a significant Q2 financial turnaround, achieving net income of $164,000 against a prior-year loss and a 16% revenue increase to $15.4 million, largely driven by strong demand for its Fabry disease treatment, Elfabrio. The company, which saw first-half sales jump 50%, reaffirmed its long-term growth outlook for Elfabrio, citing the global Fabry market's projected expansion to $3.2 billion by 2030. Protalix is also advancing its PRX-115 program into a Phase 2 trial in H2 2025 and recently gained inclusion in the Russell 2000 and 3000 indexes, signaling improving financial health and market visibility.

Analysis

Protalix BioTherapeutics (PLX) has demonstrated a significant financial turnaround in its second-quarter results, shifting to a net income of $164,000 from a $2.2 million loss in the prior-year period. This improvement is underpinned by robust commercial performance, with revenue from goods sold increasing 16% to $15.4 million, driven by strong sales of its Fabry disease treatment, Elfabrio, to its partner Chiesi. The impressive 50% year-over-year growth in first-half sales reinforces the positive commercial trajectory. Management has reaffirmed its long-term growth outlook, citing the substantial and expanding market for Fabry disease, which is projected to grow from $2.3 billion to $3.2 billion by 2030. While the company prudently cautions about fluctuating quarterly orders during the initial launch phase, it anticipates stabilizing demand and increasing market share over time. Beyond its primary revenue driver, Protalix is advancing its pipeline with PRX-115 for gout set to enter a Phase 2 trial in H2 2025, providing a potential future catalyst. The company's recent inclusion in the Russell 2000 and 3000 indexes enhances its market visibility and may attract further institutional investment, complementing a solid balance sheet with $33.4 million in cash and equivalents.

Key Decisions for Investors

• The positive shift to profitability and strong Elfabrio sales growth validate the company's commercial strategy, supporting a constructive view on the stock's fundamental momentum.
• Investors should monitor the company's caution regarding near-term order fluctuations, but recognize that the recent inclusion in the Russell indexes provides a positive technical tailwind that could increase liquidity and ownership.
• The planned initiation of the Phase 2 trial for the gout candidate PRX-115 in H2 2025 represents a key upcoming catalyst that could de-risk the pipeline and unlock further value beyond Elfabrio.
• Consider the company's cash position of $33.4 million as sufficient to fund near-term operations, including the upcoming clinical trial, mitigating immediate financing risks.